Pair Name	Liquiritigenin, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Inhibition-->Cell migration
Gene Regulation	Down-regulation	Expression	PIK3CA	hsa5290
	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Up-regulation	Expression	PTEN	hsa5728
In Vitro Model	B16-F10	Mouse melanoma	Mus musculus (Mouse)	CVCL_0159
In Vivo Model	In vivo study demonstrated the enhancement effect of LQ on CDDP suppressing lung metastasis in a mice model being inoculated by the B16F10 melanoma cells.
Result	The results suggested that LQ plays an intensive role on CDDP suppressing invasion and metastasis through regulating the PI3 K/AKT signal pathway and suppressing the protein expression of MMP-2/9.

Pair Name	Liquiritigenin, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone
Partner Name	[4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	ESR2	hsa2100
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	BT-474	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0179
Result	The ERβ ligand LQ significantly enhanced the inhibition of breast-cancer cell viability and tumor-xenograft growth by RO. The anti-tumor properties of RO may in part be due to an off-target effect that reduces ERα and increases ERβ, the latter of which can then interact with LQ to promote anti-proliferative effects. The RO + LQ combination may have value when considering novel treatment strategies for hormone-dependent breast cancer.